D. C. Douek

XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants

The paper evaluates the effectiveness of an XBB.1.5 monovalent booster vaccine, showing improved antibody binding and neutralization against SARS-CoV-2 Omicron variants.

Systems immunology of transcriptional responses to viral infection identifies conserved antiviral pathways across macaques and humans

The paper identifies conserved antiviral pathways across macaques and humans using transcriptomic data from viral infections, showing shared and virus-specific responses that inform pandemic preparedness.

RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

RBD-62, a high-affinity ACE2 antagonist, limits SARS-CoV-2 replication in both upper and lower airways in rhesus macaques without blocking memory responses or causing anti-drug immunity.

Human CCR6+ Th cells show both an extended stable gradient of Th17 activity and imprinted plasticity

The paper identifies an extended gradient of Th17 activity in human CCR6+ Th cells, showing both stable phenotypes and plasticity under different activation conditions.

mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1

This study evaluates the neutralizing efficacy of bivalent mRNA boosters against emerging SARS-CoV-2 subvariants BA.2.75.2 and BQ.1.1, showing improved protection compared to monovalent boosters.

Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques

This study shows that modulating type I interferon responses in rhesus macaques reduces SARS-CoV-2 viral load and inflammation, suggesting a potential therapeutic strategy for severe COVID-19.

A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization

This paper develops multispecific antibodies that neutralize all SARS-CoV-2 variants, including Omicron, by targeting multiple epitopes on the spike protein.

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant

This study evaluates the neutralizing activity of mRNA vaccines against the SARS-CoV-2 Omicron variant, showing reduced efficacy after the second dose but improved responses following a third dose.

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant

This study assesses neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant in convalescent and vaccinated individuals, finding it is 6.8-fold more resistant but still neutralizable.

Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants

The paper identifies ultrapotent antibodies from convalescent donors that neutralize SARS-CoV-2 variants and reduce escape mutant generation.

SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys

This study shows that SARS-CoV-2 vaccines induce neutralizing antibodies against SARS-CoV-1, SARS-CoV-2, and batCoVs in monkeys.

Human antibody immune responses are personalized by selective removal of MHC-II peptide epitopes

The paper shows that MHC-II epitope removal from BCRs correlates with antibody development, T cell help, and long-term serum antibody secretion.

Human follicular CD4 T cell function is defined by specific molecular, positional and TCR dynamic signatures.

TCF-1 regulates the stem-like memory potential of HIV-specific CD8+ T cells in elite controllers

The paper shows TCF-1 enhances HIV-specific CD8+ T cell expansion and memory properties in elite controllers.

Design of nanoparticulate group 2 influenza hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages

This study designs nanoparticle-based influenza HA stem antigens that activate unmutated B cell receptors of broadly neutralizing antibodies, potentially enabling cross-group immunity.